Suppressive effect of an analog of the antimicrobial peptide of LL‑37 on colon cancer cells via exosome‑encapsulated miRNAs

Hayashi,Miwa; Kuroda,Kengo; Ihara,Kohei; Iwaya,Takahiro; Isogai,Emiko

doi:10.3892/ijmm.2018.3875

Suppressive effect of an analog of the antimicrobial peptide of LL‑37 on colon cancer cells via exosome‑encapsulated miRNAs

Authors:
- Miwa Hayashi
- Kengo Kuroda
- Kohei Ihara
- Takahiro Iwaya
- Emiko Isogai
View Affiliations

Affiliations: Laboratory of Animal Microbiology, Graduate School of Agricultural Science, Tohoku University, Sendai, Miyagi 980‑0845, Japan
Published online on: September 13, 2018 https://doi.org/10.3892/ijmm.2018.3875
Pages: 3009-3016
Copyright: © Hayashi et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Antimicrobial peptides (AMPs) are multifunctional factors with an important role in the innate immune system. Our previous studies revealed that the human cathelicidin LL‑37 and its analog, FF/CAP18, limit the proliferation of colon cancer cell lines. In the present study, the exosomes released by HCT116 cells treated with FF/CAP18 were analyzed. After the treatment, exosomes were isolated from the culture supernatant by ultrafiltration and using the miRCURY™ Exosome Isolation Kit. Membrane vesicles 40‑100‑nm expressing CD63 and CD81 were identified before and after FF/CAP18 treatment. Exosome concentration in the culture supernatant was increased after treatment with FF/CAP18. Exosomes formed in HCT116 cells treated with FF/CAP18 induced growth suppression of the cells in a dose‑dependent manner. By contrast, the exosomes formed in non‑treated HCT116 cells did not affect cell viability. Microarray analysis of miRNA expression indicated that FF/CAP18 treatment induced increases in the expression of three miRNAs (miR‑584‑5p, miR‑1202 and miR‑3162‑5p) in both HCT116 cells and exosomes. These results suggest that FF/CAP18 treatment increases exosome formation, and that exosome‑encapsulated miRNAs suppress HCT116 cell proliferation. Exosomal miRNAs are considered to be involved in the dissemination of cell signals to control local cellular microenvironments. The present findings suggest that FF/CAP18 regulates cancer growth by modulating cell‑to‑cell communication. AMPs localize in the cytoplasm of cancer cells and enhance the expression of growth‑suppressing miRNAs. These miRNAs are also transported to other cancer cells via exosomes. Therefore, transportation of these miRNAs has the potential to suppress cancer growth. AMPs exert their effects directly by targeting cancer cells and indirectly via exosomes.

View Figures

View References

1	Zanetti M, Gennaro R, Scocchi M and Skerlavaj B: Structure and biology of cathelicidins. Adv Exp Med Biol. 479:203–218. 2000. View Article : Google Scholar : PubMed/NCBI
2	Zanetti M: The role of cathelicidins in the innate host defenses of mammals. Curr Issues Mol Biol. 7:179–196. 2005.PubMed/NCBI
3	Cowland JB, Johnsen AH and Borregaard N: hCAP-18, a cathelin/probactenecin-like protein of human neutrophil specific granules. FEBS Lett. 368:173–176. 1995. View Article : Google Scholar : PubMed/NCBI
4	Frohm M, Agerberth B, Ahangari G, Ståhle-Bäckdahl M, Lidén S, Wigzell H and Gudmundsson GH: The expression of the gene coding for the antibacterial peptide LL-37 is induced in human keratinocytes during inflammatory disorders. J Biol Chem. 272:15258–15263. 1997. View Article : Google Scholar : PubMed/NCBI
5	Bals R, Wang X, Zasloff M and Wilson JM: The peptide anti-biotic LL-37/hCAP-18 is expressed in epithelia of the human lung where it has broad antimicrobial activity at the airway surface. Proc Natl Acad Sci USA. 95:9541–9546. 1998. View Article : Google Scholar
6	Hase K, Eckmann L, Leopard JD, Varki N and Kagnoff MF: Cell differentiation is a key determinant of cathelicidin LL-37/human cationic antimicrobial protein 18 expression by human colon epithelium. Infect Immun. 70:953–963. 2002. View Article : Google Scholar : PubMed/NCBI
7	Ren SX, Cheng AS, To KF, Tong JH, Li MS, Shen J, Wong CC, Zhang L, Chan RL, Wang XJ, et al: Host immune defense peptide LL-37 activates caspase-independent apoptosis and suppresses colon cancer. Cancer Res. 72:6512–6523. 2012. View Article : Google Scholar : PubMed/NCBI
8	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
9	PDQ Adult Treatment and Editorial Board: Colon Cancer Treatment (PDQ®): Patient Version PDQ Cancer Information Summaries edn. Bethesda (MD): National Cancer Institute (US); 2002
10	Okumura K, Itoh A, Isogai E, Hirose K, Hosokawa Y, Abiko Y, Shibata T, Hirata M and Isogai H: C-terminal domain of human CAP18 antimicrobial peptide induces apoptosis in oral squamous cell carcinoma SAS-H1 cells. Cancer Lett. 212:185–194. 2004. View Article : Google Scholar : PubMed/NCBI
11	Kuroda K, Fukuda T, Yoneyama H, Katayama M, Isogai H, Okumura K and Isogai E: Anti-proliferative effect of an analogue of the LL-37 peptide in the colon cancer derived cell line HCT 116 p53+/+ and p53−/−. Oncol Rep. 28:829–834. 2012. View Article : Google Scholar : PubMed/NCBI
12	Kuroda K, Fukuda T, Krstic-Demonacos M, Demonacos C, Okumura K, Isogai H, Hayashi M, Saito K and Isogai E: miR-663a regulates growth of colon cancer cells, after administration of antimicrobial peptides, by targeting CXCR4-p21 pathway. BMC Cancer. 17:332017. View Article : Google Scholar : PubMed/NCBI
13	Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ and Lötvall JO: Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 9:654–659. 2007. View Article : Google Scholar : PubMed/NCBI
14	Skog J, Würdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M, Curry WT Jr, Carter BS, Krichevsky AM and Breakefield XO: Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. 10:1470–1476. 2008. View Article : Google Scholar : PubMed/NCBI
15	Zhou W, Fong MY, Min Y, Somlo G, Liu L, Palomares MR, Yu Y, Chow A, O’Connor ST, Chin AR, et al: Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis. Cancer Cell. 25:501–515. 2014. View Article : Google Scholar : PubMed/NCBI
16	Ogata-Kawata H, Izumiya M, Kurioka D, Honma Y, Yamada Y, Furuta K, Gunji T, Ohta H, Okamoto H, Sonoda H, et al: Circulating exosomal microRNAs as biomarkers of colon cancer. PLoS One. 9:e929212014. View Article : Google Scholar : PubMed/NCBI
17	Kloosterman WP and Plasterk RH: The diverse functions of microRNAs in animal development and disease. Dev Cell. 11:441–450. 2006. View Article : Google Scholar : PubMed/NCBI
18	Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
19	Esquela-Kerscher A and Slack FJ: Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006. View Article : Google Scholar : PubMed/NCBI
20	Redis RS, Calin S, Yang Y, You MJ and Calin GA: Cell-to-cell miRNA transfer: From body homeostasis to therapy. Pharmacol Ther. 136:169–174. 2012. View Article : Google Scholar : PubMed/NCBI
21	Sun Y, Zheng W, Guo Z, Ju Q, Zhu L, Gao J, Zhou L, Liu F, Xu Y, Zhan Q, et al: A novel TP53 pathway influences the HGS-mediated exosome formation in colorectal cancer. Sci Rep. 6:280832016. View Article : Google Scholar : PubMed/NCBI
22	Zaharie F, Muresan MS, Petrushev B, Berce C, Gafencu GA, Selicean S, Jurj A, Cojocneanu-Petric R, Lisencu CI, Pop LA, et al: Exosome-carried microRNA-375 inhibits cell progression and dissemination via Bcl-2 blocking in colon cancer. J Gastrointest Liver Dis. 24:435–443. 2015.
23	Kuroda K, Fukuda T, Isogai H, Okumura K, Krstic-Demonacos M and Isogai E: Antimicrobial peptide FF/CAP18 induces apoptotic cell death in HCT116 colon cancer cells via changes in the metabolic profile. Int J Oncol. 46:1516–1526. 2015. View Article : Google Scholar : PubMed/NCBI
24	Wu WK, Wang G, Coffelt SB, Betancourt AM, Lee CW, Fan D, Wu K, Yu J, Sung JJ and Cho CH: Emerging roles of the host defense peptide LL-37 in human cancer and its potential therapeutic applications. Int J Cancer. 127:1741–1747. 2010. View Article : Google Scholar : PubMed/NCBI
25	Kuroda K, Okumura K, Isogai H and Isogai E: The human cathelicidin antimicrobial peptide LL-37 and mimics are potential anticancer drugs. Front Oncol. 5:1442015. View Article : Google Scholar : PubMed/NCBI
26	Neville F, Cahuzac M, Konovalov O, Ishitsuka Y, Lee KYC, Kuzmenko I, Kale GM and Gidalevitz D: Lipid headgroup discrimination by antimicrobial peptide LL-37: Insight into mechanism of action. Biophys J. 90:1275–1287. 2006. View Article : Google Scholar
27	Turner J, Cho Y, Dinh NN, Waring AJ and Lehrer RI: Activities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils. Antimicrob Agents Chemother. 42:2206–2214. 1998. View Article : Google Scholar : PubMed/NCBI
28	Shahmiri M, Enciso M, Adda CG, Smith BJ, Perugini MA and Mechler A: Membrane core-specific antimicrobial action of cathelicidin LL-37 peptide switches between pore and nanofibre formation. Sci Rep. 6:381842016. View Article : Google Scholar : PubMed/NCBI
29	Savina A, Furlán M, Vidal M and Colombo MI: Exosome release is regulated by a calcium-dependent mechanism in K562 cells. J Biol Chem. 278:20083–20090. 2003. View Article : Google Scholar : PubMed/NCBI
30	Safaei R, Larson BJ, Cheng TC, Gibson MA, Otani S, Naerdemann W and Howell SB: Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells. Mol Cancer Ther. 4:1595–1604. 2005. View Article : Google Scholar : PubMed/NCBI
31	Li Li, Wei ZQ, Wang S, Chen W, Zhang Z, Chen L, Li L, Sun B, Xu GJ, et al: Overexpression of miR-584 5p inhibits proliferation and induces apoptosis by targeting WW domain-containing E3 ubiquitin protein ligase 1 in gastric cancer. J Exp Clin Cancer Res. 36:592017. View Article : Google Scholar
32	Konishi H, Fujiya M, Ueno N, Moriichi K, Sasajima J, Ikuta K, Tanabe H, Tanaka H and Kohgo Y: microRNA-26a and -584 inhibit the colorectal cancer progression through inhibition of the binding of hnRNP A1-CDK6 mRNA. Biochem Biophys Res Commun. 467:847–852. 2015. View Article : Google Scholar : PubMed/NCBI
33	Nam EJ, Lee M, Yim GW, Kim JH, Kim S, Kim SW and Kim YT: MicroRNA profiling of a CD133⁺ spheroid-forming subpopulation of the OVCAR3 human ovarian cancer cell line. BMC Med Genomics. 5:182012. View Article : Google Scholar
34	Munari E, Marchionni L, Chitre A, Hayashi M, Martignoni G, Brunelli M, Gobbo S, Argani P, Allaf M, Hoque MO, et al: Clear cell papillary renal cell carcinoma: micro-RNA expression profiling and comparison with clear cell renal cell carcinoma and papillary renal cell carcinoma. Hum Pathol. 45:1130–1138. 2014. View Article : Google Scholar : PubMed/NCBI
35	Quan Y, Song Q, Wang J, Zhao L, Lv J and Gong S: MiR-1202 functions as a tumor suppressor in glioma cells by targeting Rab1A. Tumor Biol. 39:1010428317697562017. View Article : Google Scholar
36	Meehan K and Vella LJ: The contribution of tumour-derived exosomes to the hallmarks of cancer. Crit Rev Clin Lab Sci. 53:121–131. 2016. View Article : Google Scholar
37	Lai RC, Chen TS and Lim SK: Mesenchymal stem cell exosome: A novel stem cell-based therapy for cardiovascular disease. Regen Med. 6:481–492. 2011. View Article : Google Scholar : PubMed/NCBI